Cours suspendu

Communiqués Apellis Pharmaceuticals, Inc.

Actions

APLS

US03753U1060

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 13/05/2026			Varia. 5j.	Varia. 1 janv.
41,03 ^USD	-0,07%		-.--%	+63,34%

14/05	Biogen Inc. (NasdaqGS:BIIB) a finalisé l'acquisition d'Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS) auprès de The Morningside Group Limited et d'autres actionnaires.	CI
14/05	Apellis Pharmaceuticals, Inc. annonce des changements au sein de son conseil d'administration et de ses comités	CI

Communiqués

20/04	Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS	BU
01/04	Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS	BU
31/03	Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology	GL
02/03	Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors	GL
24/02	Apellis Pharmaceuticals : Fourth Quarter and Year End 2025 Earnings Presentation	PU
24/02	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results	GL
23/02	Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference	GL
23/02	Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference	AQ
19/02	Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting	GL
10/02	Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results	GL
12/01	Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference	GL
05/01	Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
03/12	The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN	GL
25/11	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
12/11	Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years	GL
05/11	Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference	GL
30/10/25	Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results	GL
20/10/25	New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week	GL
16/10/25	Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results	GL
27/08/25	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
31/07/25	Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results	GL
29/07/25	FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older	GL
24/07/25	Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results	GL
15/07/25	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting	GL
15/07/25	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting	AQ